Semaglutide + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metabolism and Nutrition Disorder
Conditions
Metabolism and Nutrition Disorder, Obesity
Trial Timeline
Jun 4, 2018 → Mar 20, 2020
NCT ID
NCT03548987About Semaglutide + Placebo
Semaglutide + Placebo is a phase 3 stage product being developed by Novo Nordisk for Metabolism and Nutrition Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT03548987. Target conditions include Metabolism and Nutrition Disorder, Obesity.
What happened to similar drugs?
5 of 19 similar drugs in Metabolism and Nutrition Disorder were approved
Approved (5) Terminated (2) Active (14)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06041217 | Phase 3 | Completed |
| NCT05726227 | Phase 3 | Active |
| NCT05891496 | Phase 3 | Completed |
| NCT05486065 | Phase 2 | Completed |
| NCT04889183 | Phase 3 | Completed |
| NCT04979130 | Approved | Completed |
| NCT04822181 | Phase 3 | Active |
| NCT03842202 | Phase 1 | Completed |
| NCT03548987 | Phase 3 | Completed |
| NCT03357380 | Phase 1 | Completed |
| NCT03086330 | Phase 3 | Completed |
| NCT02692716 | Phase 3 | Completed |
| NCT02970942 | Phase 2 | Completed |
| NCT02906930 | Phase 3 | Completed |
| NCT02827708 | Phase 3 | Completed |
| NCT02773381 | Phase 1 | Completed |
| NCT02557620 | Phase 1 | Completed |
| NCT02305381 | Phase 3 | Completed |
| NCT02212067 | Phase 1 | Completed |
| NCT02161588 | Phase 1 | Completed |
Competing Products
20 competing products in Metabolism and Nutrition Disorder